Template:Cellulitis antibiotics: Difference between revisions
Ostermayer (talk | contribs) No edit summary |
Ostermayer (talk | contribs) (Marked this version for translation) |
||
| Line 1: | Line 1: | ||
<noinclude><languages/></noinclude> | <noinclude><languages/></noinclude> | ||
<translate> | <translate> | ||
<!--T:1--> | |||
''Tailor antibiotics by regional antibiogram''<ref>Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref> | ''Tailor antibiotics by regional antibiogram''<ref>Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref> | ||
====Outpatient==== | ====Outpatient==== <!--T:2--> | ||
<!--T:3--> | |||
''Coverage primarily for [[Special:MyLanguage/Strep|Strep]]''<br /> | ''Coverage primarily for [[Special:MyLanguage/Strep|Strep]]''<br /> | ||
<!--T:4--> | |||
''[[Special:MyLanguage/MRSA|MRSA]] coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV drug use, or SIRS''<ref name="IDSA guidelines">Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref> | ''[[Special:MyLanguage/MRSA|MRSA]] coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV drug use, or SIRS''<ref name="IDSA guidelines">Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref> | ||
*5 day treatment duration, unless symptoms do not improve within that timeframe<ref name="IDSA guidelines" /> | *5 day treatment duration, unless symptoms do not improve within that timeframe<ref name="IDSA guidelines" /> | ||
| Line 16: | Line 19: | ||
====Inpatient==== | ====Inpatient==== <!--T:5--> | ||
<!--T:6--> | |||
*[[Special:MyLanguage/Vancomycin|Vancomycin]] 20mg/kg IV q12hrs '''OR''' | *[[Special:MyLanguage/Vancomycin|Vancomycin]] 20mg/kg IV q12hrs '''OR''' | ||
*[[Special:MyLanguage/Clindamycin|Clindamycin]] 600mg IV q8hrs '''OR''' | *[[Special:MyLanguage/Clindamycin|Clindamycin]] 600mg IV q8hrs '''OR''' | ||
| Line 24: | Line 28: | ||
====Saltwater related cellulitis==== | ====Saltwater related cellulitis==== <!--T:7--> | ||
<!--T:8--> | |||
''coverage extended for [[Special:MyLanguage/Vibrio vulnificus|Vibrio vulnificus]]'' | ''coverage extended for [[Special:MyLanguage/Vibrio vulnificus|Vibrio vulnificus]]'' | ||
*[[Special:MyLanguage/Doxycycline|Doxycycline]] 100mg PO/IV q12hrs daily + [[Special:MyLanguage/Cefepime|Cefepime]] 1g IV q12hrs x 10 days | *[[Special:MyLanguage/Doxycycline|Doxycycline]] 100mg PO/IV q12hrs daily + [[Special:MyLanguage/Cefepime|Cefepime]] 1g IV q12hrs x 10 days | ||
| Line 32: | Line 37: | ||
====Freshwater related cellulitis==== | ====Freshwater related cellulitis==== <!--T:9--> | ||
<!--T:10--> | |||
''coverage extended for [[Special:MyLanguage/Aeromonas sp|Aeromonas sp]]'' | ''coverage extended for [[Special:MyLanguage/Aeromonas sp|Aeromonas sp]]'' | ||
*[[Special:MyLanguage/Ciprofloxacin|Ciprofloxacin]] 400mg IV q12hrs x 10 days | *[[Special:MyLanguage/Ciprofloxacin|Ciprofloxacin]] 400mg IV q12hrs x 10 days | ||
Latest revision as of 15:58, 27 January 2026
Tailor antibiotics by regional antibiogram[1]
Outpatient
Coverage primarily for Strep
MRSA coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV drug use, or SIRS[2]
- 5 day treatment duration, unless symptoms do not improve within that timeframe[2]
- Cephalexin 500mg PO q6hrs OR
- Clindamycin 450mg PO TID covers both Strep and Staph
- Tetracyclines (like Doxycycline) should be avoided in non-purulent cellulitis due to high rates of Strep resistance[5]
Inpatient
- Vancomycin 20mg/kg IV q12hrs OR
- Clindamycin 600mg IV q8hrs OR
- Linezolid 600mg IV q12hrs OR
- Daptomycin 4mg/kg IV once daily
coverage extended for Vibrio vulnificus
- Doxycycline 100mg PO/IV q12hrs daily + Cefepime 1g IV q12hrs x 10 days
- Ciprofloxacin 400mg IV q12hrs x 10 days
- Ciprofloxacin 750mg PO q12hrs x 10 days
coverage extended for Aeromonas sp
- Ciprofloxacin 400mg IV q12hrs x 10 days
- Ciprofloxacin 500mg PO q12hrs x 10 days
- TMP/SMX 2 DS tablets (5mg/kg) PO q12hrs x 10 days
- Ceftriaxone 1g (50mg/kg) IV q24hrs
- ↑ Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52
- ↑ 2.0 2.1 Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52
- ↑ Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.
- ↑ Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762
- ↑ Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10-20.